1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cancer Cases
4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
4.2.3 Technological Developments in Cancer Vaccines
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
4.3.2 Presence of Alternative Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Technology
5.1.1 Recombinant Cancer Vaccines
5.1.2 Whole-cell Cancer Vaccines
5.1.3 Viral Vector and DNA Cancer Vaccines
5.1.4 Other Technologies (Dendritic Cells, Antigen, etc.)
5.2 Treatment Method
5.2.1 Preventive Vaccine
5.2.2 Therapeutic Vaccine
5.3 Application
5.3.1 Prostate Cancer
5.3.2 Cervical Cancer
5.3.3 Other Applications (Liver, Skin, etc.)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aduro BioTech Inc.
6.1.2 Astellas Pharma Inc.
6.1.3 AstraZeneca PLC
6.1.4 Bristol-Myers Squibb
6.1.5 Dendreon
6.1.6 GlaxoSmithKline
6.1.7 Merck & Co. Inc.
6.1.8 OSE Immunotherapeutics
6.1.9 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Aduro BioTech Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb
- Dendreon
- GlaxoSmithKline
- Merck & Co. Inc.
- OSE Immunotherapeutics
- Sanofi